vidarabine has been researched along with Cancer of Spleen in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, M; Goto, H; Hasegawa, D; Honda, T; Kumamoto, T; Ogawa, S; Takagi, M; Terao, YM; Yamaoka, M; Yoshida, K | 1 |
| Thieblemont, C | 1 |
| Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Azuma, T; Fujita, S; Ishimura, M; Takada, K; Yamauchi, H; Yasukawa, M | 1 |
| Improta, S; Mastrullo, L; Nitrato Izzo, G; Polistina, MT; Quirino, AA; Rocco, S; Russolillo, S; Sagristani, M | 1 |
| Delarue, R; François, S; Hermine, O; Ifrah, N; Lefrère, F; Lévy, V; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
| Jaeger, U; Johnson, SA; Leblond, V; Levy, V; Oscier, DG; Owen, RG; Seymour, JF | 1 |
| Hamdi, S; Huguet, F; Laporte, F; Oksman, F | 1 |
| Bolam, S; Orchard, J; Oscier, D | 1 |
| Arnaud, MC; Otto, J; Pivot, X; Schneider, M; Tchiknavorian, X; Thyss, A | 1 |
| Belanger, C; François, S; Hermine, O; Lebas de La Cour, JC; Lefrère, F; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
2 review(s) available for vidarabine and Cancer of Spleen
| Article | Year |
|---|---|
Non-MALT marginal zone lymphomas.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Italy; L-Lactate Dehydrogenase; Lymph Nodes; Lymphocytosis; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prognosis; Splenectomy; Splenic Neoplasms; Survival Analysis; Vidarabine | 2008 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; Bone Marrow Diseases; Chemotherapy, Adjuvant; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Paraproteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2002 |
1 trial(s) available for vidarabine and Cancer of Spleen
| Article | Year |
|---|---|
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Splenic Neoplasms; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
8 other study(ies) available for vidarabine and Cancer of Spleen
| Article | Year |
|---|---|
Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
Topics: Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; DNA-Binding Proteins; Etoposide; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; Liver Neoplasms; Lymphoma, T-Cell; PAX5 Transcription Factor; Prognosis; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins; Splenic Neoplasms; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2022 |
Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphocytes; Lymphoma; Remission Induction; Splenic Neoplasms; Vidarabine | 2002 |
Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Humans; Lymphoma, B-Cell; Splenic Neoplasms; T-Lymphocytes; Vidarabine | 2004 |
Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
Topics: Adult; Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphocytes; Lymphoma; Middle Aged; Splenectomy; Splenic Neoplasms; Vidarabine | 2004 |
Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Granulocytes; Humans; Hypoglycemic Agents; Leukocyte Count; Lymphoma, B-Cell, Marginal Zone; Male; Metformin; Neutropenia; Splenic Neoplasms; Vidarabine | 2008 |
Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma; Male; Splenic Neoplasms; Vidarabine | 1997 |
Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin.
Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Humans; Lymphoma; Splenectomy; Splenic Neoplasms; Treatment Outcome; Vidarabine | 1999 |
Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Vidarabine | 2000 |